

Doravirine (*Pifeltro*)

Prepared by:

Brian R. Wood, MD

David H. Spach, MD

Last Updated: February 15, 2020

Doravirine (*Pifeltro*)

Pifeltro
[pih-FEL-tro]



100 mg

└─→ NNRTI

Dose: 1 tablet once daily with or without food

Doravirine

- **Dosage Form:** 100 mg tablet
- **Dosing:** 1 pill daily with or without food
- **With Renal Impairment**
 - No adjustment with mild, moderate, or severe impairment
- **With Hepatic Impairment**
 - No dose adjustment for Child-Pugh A or B
 - insufficient data for Child-Pugh C
- **Pregnancy**
 - Inadequate data
- **Common Adverse Effects ($\geq 5\%$)**
 - Nausea, dizziness, headache, fatigue, diarrhea, abdominal pain, and abnormal dreams.

DOR + 2 NRTIs vs. DRV + RTV + 2 NRTIs
DRIVE FORWARD

Doravirine + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs

DRIVE FORWARD: Design

DRIVE FORWARD: Study Design

- **Background:** Randomized, double-blind, phase 3 study evaluating the efficacy of doravirine versus ritonavir-boosted darunavir, both with 2NRTIs in antiretroviral-naïve adults with HIV.
- **Inclusion Criteria**
 - Age ≥ 18 years
 - Antiretroviral-naïve
 - HIV RNA $\geq 1,000$ copies/mL
 - No resistance to any study drug
 - Chronic HBV or HCV allowed
- **Regimens** (all once daily)
 - Doravirine (100 mg) + 2 NRTIs
 - Darunavir (800 mg) + Ritonavir (100 mg) + 2 NRTIs

Doravirine + 2 NRTIs
(n = 385)

Darunavir + RTV + 2 NRTIs
(n = 384)

Doravirine + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs

DRIVE FORWARD: Results

DRIVE FORWARD Baseline Characteristics


Characteristic	DOR + 2 NRTI's (n = 383)	DRV + RTV + 2 NRTI's (n = 383)
Age (years), median	34.8	35.7
Male, %	83.3	85.1
White, %	73.1	73.1
CD4 count (cells/mm ³), mean	432.6	411.9
HIV RNA, mean (log ₁₀)	4.4	4.4
HIV RNA >100,000 copies/mL, %	24.3	24.5
NRTI backbone TDF-FTC, %	86.9	87.5
NRTI backbone ABC-3TC, %	13.1	12.5

Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.

Doravirine + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs

DRIVE FORWARD: 48 Week Results

Week 48 Virologic Response (Intention-to-Treat Analysis)



Doravirine + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs

DRIVE FORWARD: 48 Week Results


Treatment Related Adverse Events in DRIVE FORWARD Through Week 48		
	Doravirine + 2 NRTIs (n = 383)	DRV + RTV + 2 NRTIs (n = 383)
Any adverse drug-related event %	31	32
Discontinued due to drug-related AE, %	1	2
Upper abdominal pain, %	2	1
Diarrhea, %	5	13
Nausea, %	7	8
Headache, %	6	3
Dizziness, %	3	2
Fatigue, %	5	2
Rash, %	2	3
Neuropsychiatric, %	6	5

Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.

Doravirine + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs

DRIVE FORWARD: Results

Change in Baseline Fasting Lipids at Week 48



Doravirine + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs

DRIVE FORWARD: Summary

Interpretation: “In treatment-naive adults with HIV-1 infection, doravirine combined with two NRTIs might offer a valuable treatment option for adults with previously untreated HIV-1 infection.”

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.

